BlackRock Amends Ionis Pharma Stake as of Dec 31, 2023
Ticker: IONS · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 874015
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, pharmaceuticals
TL;DR
**BlackRock still owns a chunk of Ionis Pharma, good sign for stability.**
AI Summary
BlackRock Inc. has updated its ownership stake in Ionis Pharmaceuticals Inc. as of December 31, 2023, through an SC 13G/A filing. This amendment (Amendment No. 2) indicates that BlackRock, a major institutional investor, continues to hold a significant position in the pharmaceutical company. For investors, this filing confirms that a large, influential asset manager maintains confidence in Ionis Pharmaceuticals, which can be a positive signal for the stock's stability and long-term outlook.
Why It Matters
This filing shows that a major institutional investor, BlackRock, continues to hold a significant position in Ionis Pharmaceuticals, signaling ongoing confidence in the company's prospects.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative risks.
Analyst Insight
Investors should note BlackRock's continued presence as a major shareholder, which can be a sign of institutional confidence, but should also conduct their own due diligence on Ionis Pharmaceuticals' fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Ionis Pharmaceuticals Inc. (company) — the subject company whose shares are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- Amendment No. 2 (number) — the specific amendment number of the filing
Forward-Looking Statements
- BlackRock will likely maintain a significant stake in Ionis Pharmaceuticals throughout 2024. (BlackRock Inc.) — medium confidence, target: 2024-12-31
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 2.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major asset management firm based in New York, NY.
What is the subject company of this filing?
The subject company is Ionis Pharmaceuticals Inc., a pharmaceutical preparations company located in Carlsbad, CA.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Ionis Pharmaceuticals Inc. is 462222100.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding IONIS PHARMACEUTICALS INC (IONS).